AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Recruitingn/aAges 12 Years - anyAllSanofi
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients aged more than or equal to (โ‰ฅ) 12 years at the time of consent. * Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20. * Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil) * Signed informed consent for registry participation by the patient or parent/legal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up. Exclusion Criteria: * Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care. * Insufficient understanding of the study by the patient and/or parent/guardian. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

82 sites
Cahaba Dermatology & Skin Health Center- Site Number : 8400006
Birmingham, United States
River Region Dermatology and Laser- Site Number : 8400041
Montgomery, United States
San Tan Allergy & Asthma- Site Number : 8400031
Gilbert, United States
Saguaro Dermatology- Site Number : 8400028
Phoenix, United States
Kern Research, Inc.- Site Number : 8400047
Bakersfield, United States
Center for Dermatology Clinical Research- Site Number : 8400014
Fremont, United States
Dermatology Research Associates - Los Angeles- Site Number : 8400020
Los Angeles, United States
Northridge Clinical Trials, LLC- Site Number : 8400009
Northridge, United States

โ€ฆand 74 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy